Cosmos Health has announced a major step towards digitising its financial infrastructure through a new partnership with Prime Ledger, a move designed to transform the company’s approximately £225 million treasury into tokenised, high-value IP assets. The collaboration aims to strengthen Cosmos Health’s position at the intersection of healthcare and digital finance, while unlocking new investment channels and improving operational transparency.
According to the company, the multi-phase initiative, scheduled to begin in Q4 2025, will introduce a secure, digital asset treasury system, yield-management capabilities, and a token issuance platform linked to Cosmos Health’s growing healthcare and wellness IP portfolio. The partnership will also integrate both on-chain and off-chain data systems to enhance reporting, compliance, and performance analytics.
Cosmos Health Chief Executive Greg Siokas said the agreement reflects continued confidence in the company’s growth prospects. Siokas also highlighted the firm’s strong acquisition pipeline, noting that Cosmos Health added more than 301,000 shares in November 2025, taking total ownership to 4,659,985 shares. Despite pressure on valuation following challenging third-quarter results, Siokas remains confident the group is “well-positioned to deliver strong global value”.
Cosmos Health
Biotech start-up Junevity has secured £15 million in Seed financing, led by Goldcrest Capital and Godfrey Capital, to advance its lead siRNA obesity treatment, JUN 01, into first-in-human trials.
JUN 01 is the first candidate to reprogramme metabolism using targeted siRNA to reduce glucose levels, improve insulin sensitivity, lower body weight, and support lean-mass retention with injections required only once every six months. The therapy works through a novel transcription factor on the company’s RESET platform, enabling durable metabolic tissue reprogramming. It is being assessed as both a standalone treatment and as a combination therapy with GLP-1 medicines.
First-in-human trials are expected to begin in late 2026, marking a significant milestone for next-generation metabolic therapeutics.
A recent PitchBook report suggests that current regulatory progress for GLP-1 drugs, particularly those from Novo Nordisk and Eli Lilly , is clearing the path for broader reimbursement access. New agreements with Medicare and Medicaid could expand eligibility to 15 million patients, reducing insurance barriers and opening opportunities for emerging cardiometabolic biotech firms.
Analysts note that while Novo Nordisk and Eli Lilly retain substantial manufacturing dominance, their entrenched supply chains may ultimately create a more predictable environment for new metabolic therapies entering the market.
Eli Lilly recently increased its full-year revenue forecast to reflect the exceptional global demand for its obesity and diabetes therapies, including Zepbound and Mounjaro.
The company now expects revenues to reach £47.25-48.975 billion. in 2025, significantly above earlier projections. International demand for GLP-1 weight-loss medications continues to surge, with Lilly reporting robust quarterly sales. Analysts point to this trend as evidence that GLP-1s are becoming long-term growth drivers rather than short-term market anomalies.
Biomea Fusion, a clinical-stage biotech company, announced that its board has approved a new inducement equity award under the Nasdaq Rule 5635(c)(4). The package includes a non-qualified stock option for 7,500 shares, issued under the 2023 Inducement Equity Plan.
Designed to strengthen recruitment and retention, the grant will support Biomea’s development of key small-molecule candidates, including ivocanib and BMF-650.
The global cardiovascular devices sector, valued at £58.275 billion in 2024 , is forecast to reach £82.8 billion by 2029, driven by ageing populations, obesity rates, and rising demand for minimally invasive procedures.
Interventional cardiology devices remain the fastest-growing category, with hospitals continuing to dominate demand. North America leads the global market, supported by major medical-device companies such as Boston Scientific, Medtronic, Abbott, Edwards Lifesciences, Johnson & Johnson, and Siemens Healthineers. Innovations including Abbott’s AVEIR leadless pacemaker and Boston Scientific’s FARAPULSE system reflect growing adoption of next-generation cardiac technologies.
Sources:
- Cosmos Health Press Release – Digital Treasury and Prime Ledger Collaboration
https://www.cosmoshealth.com
- Junevity Funding Announcement – JUN 01 siRNA Obesity Programme
https://www.junevity.com - PitchBook Analysis – GLP-1 Regulatory Landscape and Market Outlook
https://pitchbook.com - Eli Lilly Financial Outlook & GLP-1 Market Data
https://investor.lilly.com - Biomea Fusion Corporate Update – Inducement Equity Grant
https://biomeafusion.com - Global Cardiovascular Devices Market Report
https://www.marketsandmarkets.com
